Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

Thomas Powles; Mark Kockx; Alejo Rodriguez-Vida; Ignacio Duran; Simon J. Crabb; Michiel S. van der Heijden; Bernadett Szabados; Albert Font Pous; Gwenaelle Gravis; Urbano Anido Herranz; Andrew Protheroe; Alain Ravaud; Denis Maillet; Maria Jose Mendez; Cristina Suarez; Mark Linch; Aaron Prendergast; Pieter-Jan van Dam; Diana Stanoeva; Sofie Daelemans; Sanjeev Mariathasan; Joy S. Tea; Kelly Mousa; Romain Banchereau; Daniel Castellano

doi:https://doi.org/10.1038/s41591-020-0923-3

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, Michiel S. van der Heijden, Bernadett Szabados, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Pieter-Jan van Dam, Diana Stanoeva, Sofie DaelemansSanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Romain Banchereau, Daniel Castellano

Doctoral School

Research output: Contribution to journal › Comment/Letter to the editor › Academic

1 Citation (Scopus)

Abstract

In the version of this article initially published, the labels in the key to Fig. 1f (red bars, Down in responders; blue bars, Up in responders) were incorrect. The correct labels are as follows: red bars, Up in responders; blue bars, Down in responders. Also, the histopathology images in Fig. 2a were incorrect. The correct images are now provided. The errors have been corrected in the HTML and PDF versions of the article.

Original language	English
Pages (from-to)	983
Number of pages	1
Journal	Nature medicine
Volume	26
Issue number	6
Early online date	2020
DOIs	https://doi.org/10.1038/s41591-020-0923-3
Publication status	Published - 1 Jun 2020

Access to Document

https://doi.org/10.1038/s41591-020-0923-3

Cite this

Powles, T., Kockx, M., Rodriguez-Vida, A., Duran, I., Crabb, S. J., van der Heijden, M. S., Szabados, B., Pous, A. F., Gravis, G., Herranz, U. A., Protheroe, A., Ravaud, A., Maillet, D., Mendez, M. J., Suarez, C., Linch, M., Prendergast, A., van Dam, P.-J., Stanoeva, D., ... Castellano, D. (2020). Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7). Nature medicine, 26(6), 983. https://doi.org/10.1038/s41591-020-0923-3

@article{e22364039a894c1ba881317db9fd56d6,

title = "Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)",

abstract = "In the version of this article initially published, the labels in the key to Fig. 1f (red bars, Down in responders; blue bars, Up in responders) were incorrect. The correct labels are as follows: red bars, Up in responders; blue bars, Down in responders. Also, the histopathology images in Fig. 2a were incorrect. The correct images are now provided. The errors have been corrected in the HTML and PDF versions of the article.",

author = "Thomas Powles and Mark Kockx and Alejo Rodriguez-Vida and Ignacio Duran and Crabb, {Simon J.} and {van der Heijden}, {Michiel S.} and Bernadett Szabados and Pous, {Albert Font} and Gwenaelle Gravis and Herranz, {Urbano Anido} and Andrew Protheroe and Alain Ravaud and Denis Maillet and Mendez, {Maria Jose} and Cristina Suarez and Mark Linch and Aaron Prendergast and {van Dam}, Pieter-Jan and Diana Stanoeva and Sofie Daelemans and Sanjeev Mariathasan and Tea, {Joy S.} and Kelly Mousa and Romain Banchereau and Daniel Castellano",

year = "2020",

month = jun,

day = "1",

doi = "https://doi.org/10.1038/s41591-020-0923-3",

language = "English",

volume = "26",

pages = "983",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "6",

}

Powles, T, Kockx, M, Rodriguez-Vida, A, Duran, I, Crabb, SJ, van der Heijden, MS, Szabados, B, Pous, AF, Gravis, G, Herranz, UA, Protheroe, A, Ravaud, A, Maillet, D, Mendez, MJ, Suarez, C, Linch, M, Prendergast, A, van Dam, P-J, Stanoeva, D, Daelemans, S, Mariathasan, S, Tea, JS, Mousa, K, Banchereau, R & Castellano, D 2020, 'Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)', Nature medicine, vol. 26, no. 6, pp. 983. https://doi.org/10.1038/s41591-020-0923-3

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7). / Powles, Thomas; Kockx, Mark; Rodriguez-Vida, Alejo et al.
In: Nature medicine, Vol. 26, No. 6, 01.06.2020, p. 983.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

AU - Powles, Thomas

AU - Kockx, Mark

AU - Rodriguez-Vida, Alejo

AU - Duran, Ignacio

AU - Crabb, Simon J.

AU - van der Heijden, Michiel S.

AU - Szabados, Bernadett

AU - Pous, Albert Font

AU - Gravis, Gwenaelle

AU - Herranz, Urbano Anido

AU - Protheroe, Andrew

AU - Ravaud, Alain

AU - Maillet, Denis

AU - Mendez, Maria Jose

AU - Suarez, Cristina

AU - Linch, Mark

AU - Prendergast, Aaron

AU - van Dam, Pieter-Jan

AU - Stanoeva, Diana

AU - Daelemans, Sofie

AU - Mariathasan, Sanjeev

AU - Tea, Joy S.

AU - Mousa, Kelly

AU - Banchereau, Romain

AU - Castellano, Daniel

PY - 2020/6/1

Y1 - 2020/6/1

N2 - In the version of this article initially published, the labels in the key to Fig. 1f (red bars, Down in responders; blue bars, Up in responders) were incorrect. The correct labels are as follows: red bars, Up in responders; blue bars, Down in responders. Also, the histopathology images in Fig. 2a were incorrect. The correct images are now provided. The errors have been corrected in the HTML and PDF versions of the article.

AB - In the version of this article initially published, the labels in the key to Fig. 1f (red bars, Down in responders; blue bars, Up in responders) were incorrect. The correct labels are as follows: red bars, Up in responders; blue bars, Down in responders. Also, the histopathology images in Fig. 2a were incorrect. The correct images are now provided. The errors have been corrected in the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85084669096&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41591-020-0923-3

DO - https://doi.org/10.1038/s41591-020-0923-3

M3 - Comment/Letter to the editor

C2 - 32555515

SN - 1078-8956

VL - 26

SP - 983

JO - Nature medicine

JF - Nature medicine

IS - 6

ER -

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, van der Heijden MS et al. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7). Nature medicine. 2020 Jun 1;26(6):983. Epub 2020. doi: https://doi.org/10.1038/s41591-020-0923-3

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

Abstract

Access to Document

Other files and links

Cite this